ANI Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US00182C1036

SecurityANIP / ANI Pharmaceuticals, Inc.
InstitutionDriehaus Capital Management Llc
Latest Disclosed Ownership121,459 shares
Latest Disclosed Value $ 9,340,197
Driehaus Capital Management Llc reports 59.44% increase in ownership of ANIP / ANI Pharmaceuticals, Inc.

On May 15, 2026 - Driehaus Capital Management Llc filed a 13F-HR form disclosing ownership of 121,459 shares of ANI Pharmaceuticals, Inc. (US:ANIP) valued at $9,340,197 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 76,180 shares of ANI Pharmaceuticals, Inc.. This represents a change in shares of 59.44% during the quarter. The current value of the position is $9,137,361 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ANI Pharmaceuticals COM 00182C103 121,459 45,279 59.44 9,340 55.33 0.0684
2026-02-17 2025-12-31 13F ANI Pharmaceuticals COM 00182C103 76,180 -2,634 -3.34 6,014 -16.71 0.0408
2025-11-14 2025-09-30 13F ANI PHARMACEUTICALS COM 00182C103 78,814 78,814 7,219 0.0517
2018-05-15 2018-03-31 13F ANI PHARMACEUTICALS COM 00182C103 0 -3,414 -100.00 0 -100.00
2018-02-14 2017-12-31 13F ANI PHARMACEUTICALS COM 00182C103 3,414 3,414 220 0.0083
2017-02-14 2016-12-31 13F ANI PHARMACEUTICALS COM 00182C103 0 -3,160 -100.00 0 -100.00
2016-11-14 2016-09-30 13F ANI PHARMACEUTICALS COM 00182C103 3,160 3,160 0.00 210 0.0071
2015-08-14 2015-06-30 13F ANI PHARMACEUTICALS COM 00182C103 0 -57,123 -100.00 0 -100.00
2015-05-15 2015-03-31 13F ANI PHARMACEUTICALS COM 00182C103 57,123 14,505 34.03 3,573 48.69 0.1238
2015-02-13 2014-12-31 13F ANI PHARMACEUTICALS COM 00182C103 42,618 -121,269 -74.00 2,403 -48.16 0.0967
2014-11-14 2014-09-30 13F ANI PHARMACEUTICALS COM 00182C103 163,887 -65,832 -28.66 4,635 -41.42 0.1767
2014-08-14 2014-06-30 13F ANI Pharmaceuticals COM 00182C103 229,719 96,203 72.05 7,912 89.01 0.2567
2014-05-15 2014-03-31 13F ANI Pharmaceuticals COM 00182C103 133,516 133,516 4,186 0.1317
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.